The Medical Letter on Drugs and Therapeutics
Another Extended-Release Alpha2-Agonist for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an extended-release formulation of clonidine hydrochloride (Kapvay – Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha2-adrenergic agonist approved for this indication; guanfacine hydrochloride (Intuniv) was the first,1 but only clonidine is approved for use with stimulants.

STANDARD TREATMENT — A stimulant such as an amphetamine or a methylphenidate-based formulation is generally used first for treatment of ADHD.2 The immediate-release formulations of clonidine (Catapres, and others) and guanfacine (Tenex, and others), both marketed for treatment of hypertension, have been used off-label for years for treatment of ADHD, either alone or concurrently with a stimulant, particularly in children ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Extended-Release Alpha2-Agonist for ADHD
Article code: 1357c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian